Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

LZRSE-Col7A1

Cell therapy · Gene replacement · developed by Abeona Therapeutics

Phase 1/2 Most advanced trial (none active)
ABEO Developer
1 Registered trials

What is LZRSE-Col7A1?

LZRSE-Col7A1 is an engineered autologous epidermal cell therapy in which the patient's own skin cells are genetically modified ex vivo to express COL7A1 (type VII collagen), which is deficient in epidermolysis bullosa dystrophica. The engineered cells are grafted back onto the patient to restore the missing protein.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy
Mechanism
Gene replacement
Therapy area
Dermatology
Developer
Abeona Therapeutics, Inc (ABEO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01263379 Phase 1/2 Epidermolysis Bullosa Dystrophica Completed ABEO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Epidermolysis BullosaEpidermolysis Bullosa Dystrophica

More from Abeona Therapeutics

ABO-101 N/A EB-101 Phase 3 MSI-78 Phase 3 Pz-cel Phase 4 rAAV9.CMV.hNAGLU Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ABEO page.

Follow ABEO, the company behind LZRSE-Col7A1

See ABEO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABEO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.